Skip to content

Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.- The CARAMEL Study

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517751-13-01
Acronym
PHRCN2018
Enrollment
76
Registered
2024-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric disorders

Brief summary

The primary endpoint will be the total consumption of alcohol (in standard-drinks, sd) in the 28 last days (week 8 to week 12) of the study, using the A-TLFB daily self-report of alcohol drinking. The difference between the total alcohol consumption during 28 days preceding the study, and the 28 last days of the study, will be compared between the two groups.

Detailed description

Percentages of heavy drinking days (i.e., 6 standard-drinks or more) during the study period., Difference (i.e., inclusion minus end of study) in alcohol craving scores using the OCDS., Difference (i.e., inclusion minus end of study) in alcohol use disorder scores using the AUDIT-C., Difference (i.e., inclusion minus end of study) in GGT levels., Difference (i.e., inclusion minus end of study) in CDT levels., Difference (i.e., inclusion minus end of study) in PEth levels., Difference (i.e., inclusion minus end of study) in anxiety and depression (HADS) scores., Difference (i.e., inclusion minus end of study) in self-confidence to resist, quality of life (SF12v2), stigmatization, sleep quality (PSQI) scores., Difference (i.e., inclusion minus end of study) in CAP scores using ultra-sound electrography., Difference (i.e., inclusion minus end of study) in steatosis score using MRI morphometric assessment of fat composition of the liver., Difference (i.e., inclusion minus end of study) in steatosis score using SRM assessment of lipid peaks in the liver., Brain map of difference (i.e., inclusion minus end of study) in grey matter volumes in corticostriatal-limbic circuits., Brain difference (i.e., inclusion minus end of study) in cortical thickness of insula, superior temporal gyrus, dorso-lateral prefrontal cortex and anterior cingulate cortex., Difference (i.e., inclusion minus end of study) in attentional, memory and executive functions abilities using neuropsychological testing.

Interventions

DRUGCannabidiol
DRUGPlacebo Cannabidiol 50 mg/g

Sponsors

Centre Hospitalier Le Vinatier
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint will be the total consumption of alcohol (in standard-drinks, sd) in the 28 last days (week 8 to week 12) of the study, using the A-TLFB daily self-report of alcohol drinking. The difference between the total alcohol consumption during 28 days preceding the study, and the 28 last days of the study, will be compared between the two groups.

Secondary

MeasureTime frame
Percentages of heavy drinking days (i.e., 6 standard-drinks or more) during the study period., Difference (i.e., inclusion minus end of study) in alcohol craving scores using the OCDS., Difference (i.e., inclusion minus end of study) in alcohol use disorder scores using the AUDIT-C., Difference (i.e., inclusion minus end of study) in GGT levels., Difference (i.e., inclusion minus end of study) in CDT levels., Difference (i.e., inclusion minus end of study) in PEth levels., Difference (i.e., inclusion minus end of study) in anxiety and depression (HADS) scores., Difference (i.e., inclusion minus end of study) in self-confidence to resist, quality of life (SF12v2), stigmatization, sleep quality (PSQI) scores., Difference (i.e., inclusion minus end of study) in CAP scores using ultra-sound electrography., Difference (i.e., inclusion minus end of study) in steatosis score using MRI morphometric assessment of fat composition of the liver., Difference (i.e., inclusion minus end of study) in

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026